Clinical trials: Dry Skin
Sjogren's Syndrome
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
Background: An autoimmune disease is one in which the immune system attacks a person's own body. Sjogren's syndrome (SS) is an autoimmune disease. It often involves multiple systems and organs of the body.
- Trial name
- NCT04496960
- Testing
- tofacitinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Dry Eye Syndromes
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief
A study to evaluate the tolerability and acceptability of an investigational eye drop formulation in patients with Dry Eye Disease.
- Trial name
- NCT02455050
- Testing
- Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Allergan
Dry Eye Disease With Severe Keratitis
3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED)…
- Trial name
- NCT04144413
- Testing
- Open-label Ikervis, Masked Ikervis, Vehicle Comparator: Masked Vehicle
- Where
- 45 sites in Czechia, France and 5 more
- Volunteers
- 350 people
- Sponsor
- Santen SAS
Interstitial Lung Disease, Connective Tissue Disease
A Clinical Trial for CTD-ILD Treatment
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).
- Trial name
- NCT01424033
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Dry Eye Syndromes
Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease
This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.
- Trial name
- NCT01294384
- Testing
- carboxymethylcellulose sodium based New Eye Drop Formulation 1, carboxymethylcellulose sodium based New Eye Drop Formulation 2, carboxymethylcellulose sodium based Eye Drops
- Where
- 2 sites in Australia, Canada
- Volunteers
- 305 people
- Sponsor
- Allergan
Vulvodynia, Dyspareunia
Therapy to Prevent Sexual Pain in Breast Cancer Survivors
The purpose of this protocol is to determine whether pain with sexual intercourse can be reduced in menopausal, breast cancer survivors and to evaluate the effectiveness of a non-hormonal therapy (Lidocaine Liquid) vs.
- Conditions
- Vulvodynia, Dyspareunia, Breast Cancer, Menopause
- Trial name
- NCT01539317
- Testing
- Topical liquid lidocaine, Topical saline
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Dry Eye Disease (DED)
Effects of NOV03 on the Tear Film
Determine the effect of a single instillation of NOV03 on the thickness and evaporation rate of the mucus-aqueous layer of the tear film
- Trial name
- NCT05723770
- Testing
- instillation of NOV03
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Bausch & Lomb Incorporated
Congenital Heart Block, Neonatal Lupus
Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Women with antibodies to proteins called SSA/Ro and or SSB/La face a 2% chance of having a child with a life threatening heart condition regardless of whether they have very active lupus, are in remission, or have only vague…
- Conditions
- Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block
- Trial name
- PATCH (NCT01379573)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- NYU Langone Health
Dry Eye Syndrome
Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
The primary objective of this study was to assess the efficacy and safety of different doses of rhNGF when administered as eye drops to patients with dry eye.
- Trial name
- NCT02101281
- Testing
- rhNGF 20 µg/mL, rhNGF 4 µg/mL
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease
The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype…
- Trial name
- SHEEPDOG (NCT04159935)
- Testing
- iLux® system
- Where
- Canada
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Waterloo
Dry Eye Disease, Meibomian Gland Dysfunction
Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
- Conditions
- Dry Eye Disease, Meibomian Gland Dysfunction, Cataract Senile, Dry Eye Syndromes
- Trial name
- NCT06483750
- Testing
- Systane iLux Treatment
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- George Washington University
Dry Eye Syndrome, Keratoconjunctivitis Sicca
A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome
The purpose of this study is to compare acute tear production produced by the Oculeve Intranasal Lacrimal Neurostimulator with two control devices in participants with aqueous tear deficiency.
- Trial name
- NCT02680158
- Testing
- Oculeve Intranasal, Oculeve Extranasal
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Oculeve, Inc.
Geographic Atrophy, Dry Age-Related Macular Degeneration
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration…
- Trial name
- NCT02686658
- Testing
- Avacincaptad Pegol
- Where
- 78 sites in United States, Croatia and 5 more
- Volunteers
- 286 people
- Sponsor
- IVERIC bio, Inc.
Dry Eye Syndrome
Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
The purpose of this study is to evaluate the efficacy of Blink Tears and Systane used concomitantly with topical cyclosporine for the treatment of dry eye.
- Trial name
- NCT00565669
- Testing
- Cyclosporin A Restasis®, Blink tears, Systane
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Dry Eye
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
Primary objectives To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) >10mm/5min at Week 4 by testing the superiority.
- Trial name
- NCT05133180
- Testing
- Oxervate, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 104 people
- Sponsor
- Dompé Farmaceutici S.p.A
Breast Cancer, Hot Flashes
Reproductive Health Survivorship Care Plan Pilot
Most young breast cancer patients undergo chemotherapy and/or endocrine therapy, treatments that impair ovarian function and result in significant reproductive health late effects.
- Conditions
- Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms
- Trial name
- NCT02176083
- Testing
- Text message management prompts
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Diego
Dry Eye Syndrome
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03396913
- Testing
- IPL, MGX
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lumenis Be Ltd.
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.